Clinical Research Directory
Browse clinical research sites, groups, and studies.
Ustekinumab for Intestinal Behçet's Syndrome With Myelodysplastic Syndrome
Sponsor: Liu Tian
Summary
Behçet's syndrome is a systemic vasculitis. Gastrointestinal involvement in Behçet's syndrome complicated by myelodysplastic syndrome represents a rare and severe subtype for which no standardized treatment guidelines currently exist, posing significant challenges in clinical practice. Ustekinumab, a biologic agent targeting IL-12/IL-23, has demonstrated favorable efficacy in both gastrointestinal Behçet's syndrome and inflammatory bowel disease. This study aims to evaluate the efficacy and safety of ustekinumab in patients with intestinal Behçet's syndrome and coexisting myelodysplastic syndrome.
Official title: Efficacy and Safety of Ustekinumab for Intestinal Behçet's Syndrome Complicated by Myelodysplastic Syndrome
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
8
Start Date
2024-03-24
Completion Date
2026-02-23
Last Updated
2026-05-13
Healthy Volunteers
No
Interventions
Ustekinumab 90 mg
Ustekinumab will be administered subcutaneously at a dose of 90 mg at weeks 0, 4, and 8, followed by a maintenance dose of 90 mg every 12 weeks (every 3 months).
Locations (1)
Department of Rheumatology and Immunology, Peking University People's Hospital
Beijing, China